- Home
- FLC vs IPHA Comparison
FLC vs IPHA Comparison
Compare FLC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- IPHA
- Stock Information
- Founded
- FLC 2003
- IPHA 1999
- Country
- FLC United States
- IPHA France
- Employees
- FLC N/A
- IPHA N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- IPHA Health Care
- Exchange
- FLC Nasdaq
- IPHA Nasdaq
- Market Cap
- FLC 174.2M
- IPHA 160.1M
- IPO Year
- FLC N/A
- IPHA 2019
- Fundamental
- Price
- FLC $17.18
- IPHA $2.19
- Analyst Decision
- FLC
- IPHA Strong Buy
- Analyst Count
- FLC 0
- IPHA 1
- Target Price
- FLC N/A
- IPHA $11.00
- AVG Volume (30 Days)
- FLC 37.8K
- IPHA 12.6K
- Earning Date
- FLC 01-01-0001
- IPHA 09-11-2025
- Dividend Yield
- FLC 6.64%
- IPHA N/A
- EPS Growth
- FLC N/A
- IPHA N/A
- EPS
- FLC N/A
- IPHA N/A
- Revenue
- FLC N/A
- IPHA $20,831,349.00
- Revenue This Year
- FLC N/A
- IPHA $278.51
- Revenue Next Year
- FLC N/A
- IPHA $70.16
- P/E Ratio
- FLC N/A
- IPHA N/A
- Revenue Growth
- FLC N/A
- IPHA N/A
- 52 Week Low
- FLC $12.62
- IPHA $1.29
- 52 Week High
- FLC $15.45
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- FLC 60.93
- IPHA 59.91
- Support Level
- FLC $17.07
- IPHA $2.06
- Resistance Level
- FLC $17.19
- IPHA $2.28
- Average True Range (ATR)
- FLC 0.10
- IPHA 0.15
- MACD
- FLC 0.00
- IPHA 0.00
- Stochastic Oscillator
- FLC 74.14
- IPHA 33.03
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.